Potassium Supplementation to Reduce Blood Pressure

Sponsor
Oxford Brookes University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05412654
Collaborator
Suntory Beverage & Food Limited (Other)
40
2
11

Study Details

Study Description

Brief Summary

The aim of this study is to conduct a definitive trial to assess the efficacy of consuming 1L/day of water rich in potassium to reduce blood pressure in mild to moderately hypertensive adults. The objective is to assess the potential effect of the intervention on reducing systolic blood pressure. This study will comprise of a 4 week, double-blind, parallel randomised controlled trial. Participants will be adults with systolic blood pressure measurements of 130mmHg or greater. The intervention comprises advice to consume bottled water rich in potassium. The comparator will be regular bottled mineral water.This study will recruit 40 people with elevated systolic blood pressure (≥130mmHg) who are not regularly taking antihypertensive medication.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: High potassium water
  • Dietary Supplement: Control low potassium water
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Double blinded randomised controlled trialDouble blinded randomised controlled trial
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Testing the Potential Effect of a Potassium-rich Water Intervention on Blood Pressure in Mild to Moderately Hypertensive Adults: a Double-blind Randomised Controlled Trial
Anticipated Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Mar 1, 2023
Anticipated Study Completion Date :
May 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: High potassium water

All participants will be provided with bottled water for the duration of the 4 week intervention to consume 1L/day. The intervention group will receive high potassium water. Participants will be instructed to consume 1 bottle (500 mL) within 2 hours after waking up and 1 bottle (500 mL) within 2 hours before going to bed (total 1L/day). Participants will continue with the same diet and exercise patterns in their daily life similar to before participating in the study, for the whole length of the intervention.

Dietary Supplement: High potassium water
High potassium water Potassium 6.2 mg/100ml

Placebo Comparator: Low potassium control water

All participants will be provided with bottled water for the duration of the 4 week intervention to consume 1L/day. The control group will receive regular bottled mineral water. Participants will be instructed to consume 1 bottle (500 mL) within 2 hours after waking up and 1 bottle (500 mL) within 2 hours before going to bed (total 1L/day). Participants will continue with the same diet and exercise patterns in their daily life similar to before participating in the study, for the whole length of the intervention.

Dietary Supplement: Control low potassium water
Control water Potassium 0.2 mg/100ml

Outcome Measures

Primary Outcome Measures

  1. Seated home measured systolic blood pressure mm/Hg [Blood pressure will be taken at three time points through out the 4 weeks.]

    Blood pressure will me monitored by the participant at home, after detailed instruction are provided by trained researchers over Zoom. Measurements will be taken in duplicate, in the morning and again in the evening (4 times a day total) and the average values will be taken.

Secondary Outcome Measures

  1. Seated home measured diastolic blood pressure [Blood pressure will be taken at three time points through out the 4 weeks]

    Blood pressure will me monitored by the participant at home, after detailed instruction are provided by trained researchers over Zoom. Measurements will be taken in duplicate, in the morning and again in the evening (4 times a day total) and the average values will be taken.

  2. Qualitative semi-structured, part open ended survey of acceptability of trial and reported barriers [This survey will be administered on the final visit at week 4 of the trial.]

    This survey will be designed by the researchers understand the participant experience of the intervention, in order to optimise any future study expansion. This will include things that worked well and those that did not work as well, during the trial (consumption of the water, convenience, appropriateness of outcome measures, burden on daily activities and lifestyle, etc.)

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 64 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Willing and able to provide informed consent

  • Between 20 to 64 years old

  • English speaking

  • Adults who are not receiving antihypertensive pharmacological treatment

  • Recent (within 6 months) and latest systolic blood pressure measurement ≥130mmHg and/or diastolic ≥85 mmHg

  • Have access to internet and equipment for video calling

  • Able to post samples and equipment to OxBCNH

  • Physically able to take own body measurements and blood pressure

Exclusion Criteria:
  • Participation in another research study

  • Unable to read and understand the instructions provided in English

  • Unable to comply with experimental procedures or not follow testing safety guidelines

  • People with cardiovascular conditions: heart attack or stroke within the last 3 months, heart failure of grade II New York Heart Association and more severe, or prolonged QT syndrome, angina, arrhythmia or atrial fibrillation.

  • Uncontrolled type 2 diabetes (HbA1c> 9%)

  • Type 2 diabetes controlled using exogenous insulin

  • Previous or current diagnosis of diabetes complications such as nephropathy, retinopathy and neuropathy.

  • People with type 1 diabetes

  • Currently on any medication that may lead to hyperkalemia or fluid retention

  • Currently being assessed for diagnosis of hypertension (not receiving treatment for high blood pressure)

  • Already on clinician/HCP supervised diet or restricted diet

  • They are planning on going away from home (holiday or other) during the 4 week intervention period and will not be able to take water during this time.

  • Currently prescribed antihypertensive medications, or have been in the last 6 weeks

  • Chronic kidney disease stage 1 (G1A2 or G1A3), 2 (G2A2 or G2A3), 3a, 3b, 4 or 5 based on UKKA (we will ask whether participants have been diagnosed with kidney disease by a clinician based on this criteria)

  • They are planning to go on a diet or begin taking supplements containing potassium during the intervention

  • Pregnant women (including women suspected of being pregnant) and breast-feeding woman.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Oxford Brookes University
  • Suntory Beverage & Food Limited

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Shelly Coe, Senior Lecturer in Nutrition, Oxford Brookes University
ClinicalTrials.gov Identifier:
NCT05412654
Other Study ID Numbers:
  • 221579
First Posted:
Jun 9, 2022
Last Update Posted:
Jun 9, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Shelly Coe, Senior Lecturer in Nutrition, Oxford Brookes University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 9, 2022